Case File
efta-efta00967177DOJ Data Set 9OtherFrom: Jeffrey Epstein <jeevacationggmail.com>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00967177
Pages
4
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <jeevacationggmail.com>
To: Alan S Halperin cj
Subject: Re: BFP Valuation 6/7/07
Date: Thu, 15 Aug 2013 14:07:58 +0000
>
we can discuss when you have more time, a house grat, has the same type issues,
On Thu, Aug 15, 2013 at 8:02 AM, Alan S Halperin <
> wrote:
Thanks, Jeffrey. As for the discount, I have the following comments:
1. I think we may be confusing the discounts taken. Let's see what discount was taken when he
created the 2009 GRAT (which occurred after the restructuring). The current discount in fact may be
less than that which previously was taken.
2. Ultimately, it will be up to the appraiser as to the appropriate discount. While the appraiser will
accept input, the appraiser must feel comfortable with its conclusion.
3. The appraiser will not want to be inconsistent with discounts taken with respect to similar
interests.
4. Given the lock-up and other restrictions, I do not feel uncomfortable with the preliminary advise
given.
5. Let's wait and see a preliminary report. Since the documentation for the swap -- the substitution
document, promissory note and assignment -- can be done now without a set value, we do not need
resolve this issue today.
I agree that placing art into a GRAT likely is not subject to sales tax. This is so because a sales tax
is triggered only if consideration is received. Here, the transfer is a gratuitous transfer, presumably
without consideration. However, I recall some old case or ruling in NY where the NY taxing authority
took the position that the funding of a CRT or GRAT with real property was an exchange for
consideration (the right to receive an annuity) for purposes of the NY real property transfer and gains
tax. We could try to track down that case or ruling if relevant.
In any event, if the art is used as currency to pay an annuity, I fear the distribution, in-kind, in
satisfaction of the annuity will trigger a sales tax. Here, there is an exchange for consideration.
Also, we need to consider whether the use of the art during the GRAT term is permitted under the
GRAT rules. On the one hand, the regulations anticipate that it is possible for the grantor to retain
something greater than just the annuity amount. However, the example in the regs only deals with
retaining the greater of the annuity amount and income. Since the GRAT rules are very specific, we
should proceed with caution before going outside the specified rules.
IRS Circular 230 disclosure:
To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal
tax advice contained in this communication (including any attachments) is not intended or written to
be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue
Code or (ii) promoting, marketing or recommending to another party any transaction or matter
EFTA00967177
addressed herein.
Click Here for More Information
Alan S. Halperin I Partner
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas I New York, NY 10019-6064
212 373-3313 Direct Phone
212 492-0313 (Direct Fax)
From:
"Jeffrey Epstein" <jeevacation(komail.com>
To:
Alan S HalperinfPaufWeiss@PaulWeiss
08/15/2013 09:30 AM
Subject:
Re: BFP Valuation 6/7/07
as we will use the same discount putting it into the grats, i would prefer a 25 % number, i rarely take that
large a discount. i am considering new grats that put in both stock and art. are you comfortable that the art on
transfer does not trigger sales tax.
On Thu, Aug 15, 2013 at 6:33 AM, Alan S Halperin <
> wrote:
I suspect that the discounts reflected in the attachment reflect the discounts relating to BFP. The
biggest items reflected is AMH. I suspect that, in arriving at the value of AMH, there is a discount
embedded in the analysis.
IRS Circular 230 disclosure:
To ensure compliance with requirements imposed by the IRS, we inform you that any U.S. federal
tax advice contained in this communication (including any attachments) is not intended or written to
be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue
Code or (ii) promoting, marketing or recommending to another party any transaction or matter
addressed herein.
Click Here for More Information
Alan S. Halperin I Partner
Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas I New York, NY 10019-6064
1212) 3733313 (Direct Phone) l (212) 492-0313 (Direct Fax)
From:
'Eileen Alexandersorr
To:
Alan S
"'Ada Clapp
- Jeffrey Epstein' <jeevacationagmail.com>, Jessica
Soojian/PaulWeiss@PAULWEISS
08/15/2013 08:25 AM
Subject:
BFP Valuation 617107
EFTA00967178
Original Message
From: NY_730_11_XRX_COPYROOM (mailto:•
Sent: Thursday, August 15, 2013 8:06 AM
To: Eileen Alexanderson
Subject: Scan from a Xerox Color
Please open the attached document. It was scanned and sent to you using a Xerox Color.
Number of Images: 7
Attachment File Type: PDF
Device Name: NY 730 11 XRX COPYROOM
_
Device Location:
For more information on Xerox products and solutions, please visit
This email and any files transmitted with it are confidential
and intended solely for the person or entity to whom they are
addressed and may contain confidential and/or privileged
material. Any review, retransmission, dissemination or
other use of, or taking of any action in reliance upon this
information by persons or entities other than the intended
recipient is prohibited. If you have received this email in
error please contact the sender and delete the material from
any computer.
Apollo Global Management, LLC
This message is intended only for the use of the Addressee and may contain information that
is privileged and confidential. If you are not the intended recipient, you are hereby
notified that any dissemination of this communication is strictly prohibited. If you have
received this communication in error, please erase all copies of the message and its
attachments and notify us immediately.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
This message is intended only for the use of the Addressee and may contain information that
is privileged and confidential. If you are not the intended recipient, you are hereby
EFTA00967179
notified that any dissemination of this communication is strictly prohibited. If you have
received this communication in error, please erase all copies of the message and its
attachments and notify us immediately.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00967180
Technical Artifacts (10)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
jeevacationagmail.comDomain
jeevacationggmail.comDomain
komail.comEmail
[email protected]Email
[email protected]Phone
(212) 492-0313Phone
1212) 3733313Phone
212 373-3313Phone
212 492-0313Wire Ref
reflectedRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.